KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.

Alejandro Hoberman, Jibran Atwi, Peter Silas, Rosa Prato, Samantha Bosis, Judith M Martin, Isabelle Lechevin, Mariapia Possidente, Sara Manzella, Luca Moraschini, Maria Lattanzi, Pavitra Keshavan

Hum Vaccin Immunother 22(1) 2683201

PMID42262312
PMCIDPMC13251518
DOI10.1080/21645515.2026.2683201
发表日期2026-06-09
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:AI 判定为 forest plot;Figure 3.:非 KM 图。
摘要

摘要

Meningococcal vaccination of adolescents/young adults is recommended in various countries, including the United States (US). This phase 3b, observer-blind study (NCT04318548) evaluated the safety, reactogenicity, and immunogenicity of serogroup B vaccine, 4CMenB, and quadrivalent conjugate vaccine, MenACWY-CRM, when co-administered to healthy individuals aged 16-18 y, as per US Advisory Committee on Immunization Practices recommendations. Adolescents, who had received MenACWY vaccination ≥4 y previously, were randomized (N = 940; 1:1:1) to one of three groups to assess co-administration versus 4CMenB and MenACWY-CRM administered alone. Co-primary objectives were to demonstrate the non-inferiority of antibody responses after concomitant administration to antibody responses after 4CMenB (two doses administered 2 months apart) and MenACWY-CRM (single dose), as measured by human serum bactericidal assay (hSBA). Vaccine safety and reactogenicity were assessed as another primary objective. The co-primary endpoints were met: the lower limit of 2-sided 95% confidence intervals for all between-group ratios of hSBA geometric mean titers was >0.5 for the concomitant administration group versus 4CMenB group and MenACWY-CRM group. hSBA data after two 4CMenB doses and one MenACWY-CRM dose showed comparable between-group geometric mean ratios versus baseline, and percentages of participants with 4-fold rises in titers and titers ≥lower limit of quantitation. The safety profile of 4CMenB co-administered with MenACWY-CRM was comparable with that of 4CMenB administered alone. In conclusion, 4CMenB and MenACWY-CRM co-administration was well tolerated in adolescents aged 16-18 y and immune responses were comparable versus administration of each vaccine alone, which is consistent with a previous study of co-administration in infants.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Participant flow chart.
非 KM Figure
Figure 2.Demonstrated non-inferiority of immune responses following 4CMenB and MenACWY-CRM administered concomitantly to each vaccine alone (per-protocol set). (a) Non-inferiority to 4CMenB alone: between-group ratios of hSBA GMTs for 4 serogroup B indicator strains. (b) Non-inferiority to MenACWY-CRM alone: between-group ratios of hSBA GMTs for serogroups A, C, W, and Y.
非 KM Figure
Figure 3.Percentages of participants reporting each solicited local adverse event by vaccine injection site (graph a) and each solicited systemic adverse event (graph b) during the 7-day period after vaccination at study visit 1.
非 KM Figure